Skip to main content
Clinical Trials/NCT04364867
NCT04364867CompletedPhase 4

Randomized Clinical Trial of Exparel vs Pain Pump for Post-operative Pain Control After Total Shoulder Arthroplasty

Norton Healthcare1 site in 1 country102 target enrollmentStarted: August 12, 2020Last updated:
Conditions
Interventions
Drugs

Trial Snapshot

Phase
Phase 4
Status
Completed
Enrollment
102
Locations
1
Primary Endpoint
Pain Score in the 24 Hours After Surgery

Study Overview

Brief Summary

The primary objective of this study is to determine if Exparel leads to better pain scores at 24, 48 and 72 hours after Total Shoulder Arthroplasty (TSA) compared to a pain pump. Secondary objectives are (1) to determine if patients on Exparel use less narcotics and (2) have earlier return of functional use of the involved arm after surgery compared to the pain pump and (3) if use of Exparel leads to cost savings

METHODS

Sample size:

Based on prior studies on anesthetics for TSA, the mean worst pain score in the 24 hours after surgery was 5.4, based on a 0 to 10 scale. To detect a change of 2 points, alpha of 0.05, beta of 0.80, a sample size of 51 subjects in each group will be required. To account for drop-outs, a total of 60 subjects in each arm will be enrolled.

Inclusion criteria Patients undergoing unilateral primary TSA or reverse TSA Indication for surgery is osteoarthritis, rotator cuff arthropathy or massive irreparable rotator cuff tears Surgery performed by the Principal Investigator Anesthesia administered by Co-Principal Investigator Willing and able to sign an Informed Consent Exclusion criteria Indication for surgery is fracture Comorbid psychiatric diagnosis requiring therapy and/or medication except anxiety or depression Comorbid chronic pain syndrome (reflex sympathetic dystrophy, fibromyalgia) Has hepatic disease On workers compensation/disability/litigation Known adverse reaction to medications to be administered On long-acting narcotic pain medication (including extended release narcotic pain medications and methadone) Home Oxygen requirement whether as needed or scheduled. Contralateral Phrenic Nerve paralysis / incompetence. Body Mass Index ≥ 50 Randomization will be a varied blocked randomization with blocks of 12, 15 and 18 using sealed envelopes

Treatment arms:

Control: Pain catheter based pain control. Subject will receive an interscalene block with Ropivicaine 0.5% (20cc), and then a pain pump attached in the Post Anesthesia Care Unit infusing at 4cc/hr. The patient will go home with that device until it runs out.

Interventional: Single shot Exparel 10cc (133mg) mixed with 10cc of 0.5% Bupivicaine

Both arms will receive the same multimodal analgesia medications preoperatively. Celebrex 400mg PO, Gabapentin 600mg PO, Tylenol 1 gram PO, unless contraindicated.

Detailed Description

The primary objective of this study is to determine if Exparel leads to better pain scores at 24, 48 and 73 hours after TSA compared to a pain pump. Secondary objectives are (1) to determine if patients on Exparel use less narcotics and (2) have earlier return of functional use of the involved arm after surgery compared to the pain pump and (3) if use of Exparel leads to cost savings

METHODS

Sample size:

Based on prior studies on anesthetics for TSA, the mean worst pain score in the 24 hours after surgery was 5.4, based on a 0 to 10 scale. To detect a change of 2 points, alpha of 0.05, beta of 0.80, a sample size of 51 subjects in each group will be required. To account for drop-outs, a total of 60 subjects in each arm will be enrolled.

Inclusion criteria Patients undergoing unilateral primary TSA or reverse TSA Indication for surgery is osteoarthritis, rotator cuff arthropathy or massive irreparable rotator cuff tears Surgery performed by the Principal Investigator Anesthesia administered by Co-Principal Investigator Willing and able to sign an Informed Consent Exclusion criteria Indication for surgery is fracture Comorbid psychiatric diagnosis requiring therapy and/or medication except anxiety or depression Comorbid chronic pain syndrome (reflex sympathetic dystrophy, fibromyalgia) Has hepatic disease On workers compensation/disability/litigation Known adverse reaction to medications to be administered On long-acting narcotic pain medication (including extended release narcotic pain medications and methadone) Home Oxygen requirement whether as needed or scheduled. Contralateral Phrenic Nerve paralysis / incompetence. Body Mass Index ≥ 50 Randomization will be a varied blocked randomization with blocks of 12, 15 and 18 using sealed envelopes

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
None

Eligibility Criteria

Ages
18 Years to 70 Years (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Patients undergoing unilateral primary TSA or reverse TSA
  • Indication for surgery is osteoarthritis, rotator cuff arthropathy or massive irreparable rotator cuff tears
  • Surgery performed by the Principal Investigator
  • Anesthesia administered by Co-Principal Investigator
  • Willing and able to sign an Informed Consent
  • Exclusion criteria
  • Indication for surgery is fracture
  • Comorbid psychiatric diagnosis requiring therapy and/or medication except anxiety or depression
  • Comorbid chronic pain syndrome (reflex sympathetic dystrophy, fibromyalgia)
  • Has hepatic disease
  • On workers compensation/disability/litigation
  • Known adverse reaction to medications to be administered
  • On long-acting narcotic pain medication (including extended release narcotic pain medications and methadone)
  • Home Oxygen requirement whether as needed or scheduled.
  • Contralateral Phrenic Nerve paralysis / incompetence.
  • Body Mass Index ≥ 50

Exclusion Criteria

  • Not provided

Arms & Interventions

Exparel

Experimental

Single shot Exparel 10cc (133mg) mixed with 10cc of 0.5% Bupivicaine

Intervention: Exparel (Drug)

Pain pump

Active Comparator

Subject will receive an interscalene block with Ropivicaine 0.5% (20cc), and then a pain pump attached in the Post Anesthesia Care Unit infusing at 4cc/hr. The patient will go home with that device until it runs out.

Intervention: Pain Pump (Drug)

Outcomes

Primary Outcomes

Pain Score in the 24 Hours After Surgery

Time Frame: 24 hours after surgery

Worst pain score (0 \[none\] to 10 \[worst possible\]) in the 24 hours after surgery

Secondary Outcomes

  • Pain Score in the 48 Hours After Surgery(48 hours)
  • Cumulative Morphine Milligram Equivalents at 24 Hours(24 hours)
  • Cumulative Morphine Milligram Equivalents at 48 Hours(48 hours)
  • Cumulative Morphine Milligram Equivalents at 72 Hours(72hours)
  • Pain Score in the 72 Hours After Surgery(72 hours)

Investigators

Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (1)

Loading locations...

Similar Trials

Exparel for Total Shoulder Arthroplasty | Clinical Trial